Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus.
diabetes
liver fibrosis
pSWE
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
13
06
2022
revised:
26
07
2022
accepted:
27
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Background and Objectives: Non-alcoholic fatty liver disease (NAFLD)-related severe liver fibrosis is associated with a higher risk of progressing to decompensated cirrhosis and hepatic failure and developing NAFLD-related hepatocellular carcinoma (HCC), particularly in populations with diabetes. Our pilot study aims to evaluate the performances of various noninvasive methods in predicting liver fibrosis in a population of patients with diabetes and to establish a new scoring system for the prediction of severe fibrosis (>F3). Materials and Methods: A total of 175 patients with diabetes were enrolled for liver fibrosis evaluation. Using the degree of agreement (concordance) between a noninvasive score based on serum biomarkers (NAFLD fibrosis score) and point shear-wave elastography (pSWE) as the reference method, we generated receiver operating characteristic (ROC) curves and performed a multivariate analysis to predict severe liver fibrosis. Results: In our population of patients with diabetes, gamma-glutamyltransferase (GGT), age, body mass index (BMI), the homeostatic model assessment of insulin resistance (HOMA-IR), and glycosylated hemoglobin (HbA1C) were significant predictors for the diagnosis of the F3/F4 group (area under the ROC: 0.767, 0.743, 0.757, 0.772, and 0.7, respectively; p < 0.005 for all). Moreover, the combined composite score (the sum of GGT, age, BMI, HOMA index, and HbA1C) had the highest diagnostic performance at a cut-off value of 3 (AUROC—0.899; p < 0001). The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were 91.20%, 79%, 79%, and 89%, respectively, and 89% of patients were correctly classified as having severe liver fibrosis. In contrast with the Fibrosis 4 (FIB-4) score and the AST-to-platelet ratio index (APRI), the composite score had the best accuracy in discriminating advanced fibrosis. Conclusions: The proposed composite score had a reliable and acceptable diagnostic accuracy in identifying patients with diabetes at risk of having severe fibrosis using readily available laboratory and clinical data.
Identifiants
pubmed: 36010180
pii: diagnostics12081829
doi: 10.3390/diagnostics12081829
pmc: PMC9406388
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40
pubmed: 24768810
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
World J Gastroenterol. 2019 Oct 28;25(40):6053-6062
pubmed: 31686762
Clin Gastroenterol Hepatol. 2021 Nov 9;:
pubmed: 34768009
J Diabetes Investig. 2021 Nov;12(11):2019-2027
pubmed: 33943028
Aliment Pharmacol Ther. 2007 Sep 15;26(6):821-30
pubmed: 17767466
Int J Low Extrem Wounds. 2021 Jun;20(2):98-103
pubmed: 33353439
Liver Int. 2017 Sep;37(9):1389-1396
pubmed: 28235154
Radiology. 2020 Aug;296(2):263-274
pubmed: 32515681
Transl Gastroenterol Hepatol. 2019 Oct 09;4:72
pubmed: 31728429
Obesity (Silver Spring). 2009 Sep;17(9):1696-701
pubmed: 19360015
Hepatology. 2009 Nov;50(5):1403-11
pubmed: 19670414
J Hypertens. 2020 Jun;38(6):982-1004
pubmed: 32371787
Semin Liver Dis. 2020 Nov;40(4):331-338
pubmed: 32526784
J Hepatol. 2011 Sep;55(3):666-672
pubmed: 21256907
J Hepatol. 2012 May;56(5):1171-1180
pubmed: 22245903
Eur J Radiol. 2014 Feb;83(2):268-72
pubmed: 24360231
J Clin Transl Hepatol. 2017 Sep 28;5(3):261-271
pubmed: 28936407
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
Diabet Med. 2007 Jan;24(1):1-6
pubmed: 17227317
Hepatology. 2017 Nov;66(5):1486-1501
pubmed: 28586172
Am J Gastroenterol. 2009 Apr;104(4):861-7
pubmed: 19293782
Diabetes Care. 2007 Mar;30(3):734-43
pubmed: 17327353
J Viral Hepat. 2012 Feb;19(2):e212-9
pubmed: 22239521
J Obes Metab Syndr. 2022 Mar 30;31(1):1-3
pubmed: 35332113
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Diabetes Care. 2021 Feb;44(2):399-406
pubmed: 33355256
Dis Model Mech. 2009 May-Jun;2(5-6):231-7
pubmed: 19407331
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42
pubmed: 27729660
Diabetes Care. 2015 Jul;38(7):1347-55
pubmed: 25887357
PLoS One. 2020 Jan 15;15(1):e0227358
pubmed: 31940395
J Assoc Physicians India. 2009 Mar;57:205-10
pubmed: 19588648
Sci Rep. 2021 Dec 21;11(1):24372
pubmed: 34934162
Porto Biomed J. 2020 Dec 03;5(6):e101
pubmed: 33299950
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Hepatology. 2008 Feb;47(2):455-60
pubmed: 18038452
World J Gastroenterol. 2013 Aug 14;19(30):4841-9
pubmed: 23946588
J Clin Med. 2021 Aug 22;10(16):
pubmed: 34442032
Best Pract Res Clin Gastroenterol. 2017 Apr;31(2):129-141
pubmed: 28624101
Abdom Imaging. 2015 Apr;40(4):698-708
pubmed: 25690689
Exp Ther Med. 2020 Sep;20(3):2387-2391
pubmed: 32765720
Liver Int. 2021 Feb;41(2):261-270
pubmed: 32946642
Ultrasonography. 2020 Jan;39(1):52-59
pubmed: 31623416
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Front Med (Lausanne). 2021 Apr 14;8:615978
pubmed: 33937277
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Sci Rep. 2022 Jan 7;12(1):283
pubmed: 34997159
World J Hepatol. 2015 Nov 8;7(25):2610-8
pubmed: 26557954
Antioxidants (Basel). 2021 Dec 29;11(1):
pubmed: 35052583
World J Gastroenterol. 2009 Nov 28;15(44):5525-32
pubmed: 19938190